DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Biobanking: Technologies and Global Markets" report to their offering.
The global market for biobanking technologies was valued at $186.3 billion in 2015. This market is expected to increase from $198.2 billion in 2016 to $240.2 billion in 2021 at a compound annual growth rate (CAGR) of 3.9% for 2016-2021.
This report provides an overview of the global markets for biobanking, the storage of biological samples for the future. It includes analyses of global market trends, with data from 2015, estimates for 2016 and projections of compound annual growth rates (CAGRs) through 2021. It also contains detailed analyses of how biobanks can lead to new products for specific diseases to overall industry trends.
Scope of the Report:
- Breakdowns of the biobanking market by product, disease category, and geographic region or country.
- New products approved by the FDA, and those products expected to be approved within the forecast period.
- Analysis of the leading competitors, as well as emerging companies in the current worldwide biobanking market.
-
Profiles of the manufacturers of leading products, and their specific
product strategies are outlined.
Companies Mentioned:
- Abbott Laboratories Inc.
- Affymetrix, Inc.
- Asterand Plc
- Astrazeneca Ltd
- Bayer Schering Pharma Ag
- Biochain-Genomics
- Biostorage Technologies, Inc.
- Boehringer Ingelheim Gmbh
- Bristol-Myers Squibb Co
- Daiichi Sankyo Company, Ltd
- Eli Lilly And Company
- Exiqon Life Sciences
- Glaxosmithkline
- Johnson & Johnson Ltd
- Millennium Pharmaceuticals
- Merck & Co.
- Novartis AG
- Pfizer Inc
- F. Hoffman-La Roche AG
- Sanofi-Aventis
- Scipac
- Takeda Pharmaceuticals Ltd
-
Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
1: Introduction - Complimentary
2: Summary - Complimentary
3: Overview
4: Overview Of Biobank Applications
5: Current Biobanks Worldwide
6: Disease-Based Biobanks
7: Population Based Biobanks
8: For-Profit Biobank Companies
9: The Limitations Of Biobanks
10: Regulatory Dynamics, Intellectual Property, Ethical Considerations
11: Biobank Markets Forecast By Segment And Region
12: Detailed Description Of The Use Of Biomarkers
13: Company Analysis
For more information about this report visit http://www.researchandmarkets.com/research/97cd98/biobanking
